Company Active LTD

Company profile

Fuse Diagnostics Limited

Fuse

Fuse Diagnostics Limited is a UK company with status active founded in 2022 based in East of England.

CRN
14516327
Founded
2022
Age
3

Overview

Legal name
FUSE DIAGNOSTICS LIMITED
Region
East of England
Registered address
10A HARDING WAY
SAINT IVES
CAMBRIDGESHIRE
ENGLAND
PE27 3WR
Insolvency history
No

Latest accounts

Financial period: 1 Jan 2024 to 31 Dec 2024

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
10

Company events

Reference milestones and recent Companies House filing stream events.

9 events
01 Dec
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

03 Jul
2026

Memorandum Articles

Incorporation

MA | Transaction MzUyNzgxMTk4MGFkaXF6a2N4 | Paper/PDF filed

Published 03 Jul 2026 23:07

03 Jul
2026

Resolution

Resolution

RESOLUTIONS | Transaction WUY0U0I1TlZhZGlxemtjeA | Paper/PDF filed

Published 03 Jul 2026 23:07

17 Nov
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

24 Nov
2024

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzQ0NDcxOTk2NWFkaXF6a2N4

Published 24 Nov 2024 10:04

26 Aug
2024

Accounts With Accounts Type Micro Entity

Accounts Analysed

AA | Transaction MzQzMzM5MTk4NWFkaXF6a2N4

Published 26 Aug 2024 21:05

30 Nov
2022

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2023
Funded years
2023, 2024
Age at first award
0 years

Projects

2024 Collaborative R&D Lead participant

Development of an Instrument-Free Molecular Diagnostic Test for Chlamydia and Gonorrhoea

1 Jun 2024 to 30 Nov 2025

Awarded
£453,984
Total cost £648,549

Chlamydia (CT) and Gonorrhoea (NG) are the two most prevalent sexually transmitted infections, with 129m and 82m cases worldwide in 2020, respectively. Most CT/NG infections are asymptomatic yet if left untreated can cause pelvic inflammatory disease, leading to infertility and ectopic pregnancy. The infection rate in developed countries has increased per...

2023 Collaborative R&D Lead participant

Preparing for the Next Pandemic - a Rapid, Low-Cost, Instrument-Free Molecular Diagnostic Test for Respiratory Pathogens

1 Nov 2023 to 30 Apr 2025

Awarded
£349,245
Total cost £498,921

In this project we are developing a next-generation instrument-free molecular diagnostic test for seasonal respiratory viruses (Flu, COVID-19 and RSV) with potential to transform management of the next pandemic. The COVID-19 pandemic highlighted the fundamental flaws with conventional diagnostic tests for respiratory viruses. Whilst laboratory PCR (molecu...

2023 Grant for R&D Lead participant

Engineering Enzymes to Transform Molecular Diagnostics

1 Jun 2023 to 31 Oct 2023

Awarded
£49,530
Total cost £49,530

This project is focussed on engineering enzymes to realise a highly innovative instrument-free molecular diagnostic testing platform. The COVID-19 pandemic highlighted the flaws with conventional approaches to the detection of respiratory viruses. Whilst laboratory PCR (molecular) tests exhibit gold-standard performance they require specialist equipment a...

Product types

Collaborative R&D Grant for R&D